New blood marker could help doctors catch sepsis days sooner

NCT ID NCT07232784

Completed Diagnosis Sponsor: Fapon Biotech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether measuring a protein called PSP in the blood can help doctors recognize sepsis earlier in ICU patients at high risk. Researchers enrolled 250 adults in China, taking daily blood samples until sepsis was diagnosed or ruled out. The goal was to see if PSP levels could predict sepsis up to three days before standard diagnosis, potentially leading to faster treatment and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pancreatic stone protein (PSP) blood test
What this could lead to: If successful, this could give doctors a new tool to diagnose sepsis days earlier, allowing quicker treatment and potentially saving lives.
What could go wrong: This is an observational study, not a treatment trial. The test may not prove accurate enough in real-world settings, and results from 250 patients in China may not apply to all ICU populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT PATIENTS AT HIGH RISK OF SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT PATIENTS AT HIGH RISK OF SEPSIS

Contacts and locations

Locations

Shenzhen Third People's Hospital

Shenzhen, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
Zhuhai People's Hospital

Zhuhai, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.